Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Asparagine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 known ✓ | P39086 | 7/20 | 0.52 |
| ▸ | GRIK2 known ✓ | Q13002 | 4/20 | 0.52 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.48 |
| ▸ | GRIA4 known ✓ | P48058 | 4/20 | 0.45 |
| ▸ | GRIK3 known ✓ | Q13003 | 4/20 | 0.45 |
| ▸ | GRIK5 known ✓ | Q16478 | 4/20 | 0.45 |
| ▸ | GRIA2 known ✓ | P42262 | 3/20 | 0.44 |
| ▸ | GRIA1 known ✓ | P42261 | 2/20 | 0.44 |
| ▸ | GRIA3 known ✓ | P42263 | 1/20 | 0.44 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.52 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.48 |
| ▸ | GGT1 | P19440 | 4/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Asparagine SCHEMBL28655930 | 1.00 | ALOX15 (0.54) | ALOX15BLMPMP22KMT2AGRIK1 | |
| Asparagine SCHEMBL29449905 | 1.00 | ALOX15 (0.54) | ALOX15BLMPMP22KMT2AGRIK1 | |
| Asparagine SCHEMBL656714 | 1.00 | ALOX15 (0.54) | ALOX15BLMPMP22KMT2AGRIK1 | |
| Asparagine SCHEMBL28655929 | 1.00 | ALOX15 (0.54) | ALOX15BLMPMP22KMT2AGRIK1 | |
| Asparagine SCHEMBL50255 | 1.00 | ALOX15 (0.54) | ALOX15BLMPMP22KMT2AGRIK1 | |
| Asparagine SCHEMBL656713 | 1.00 | ALOX15 (0.54) | ALOX15BLMPMP22KMT2AGRIK1 | |
| Asparagine SCHEMBL50254 | 1.00 | ALOX15 (0.54) | ALOX15BLMPMP22KMT2AGRIK1 | |
| Asparagine SCHEMBL28196111 | 0.97 | ALOX15 (0.52) | ALOX15BLMPMP22KMT2AGRIK1 | |
| Asparagine SCHEMBL31634581 | 0.97 | ALOX15 (0.52) | ALOX15BLMPMP22KMT2AGRIK1 | |
| Asparagine SCHEMBL150535 | 0.97 | ALOX15 (0.56) | ALOX15BLMPMP22KMT2AGRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12152031-B2 | Biodefense agents | BioVersys AG (CH) | 2024-11-26 | — | — | US | disclosed |
| US-12104022-B2 | Chiral resolution method mimicking magnetic beneficiation and the magnetic nano-inhibitors for selective enrichment | PEKING UNIVERSITY (CN) | 2024-10-01 | — | — | US | disclosed |
| CN-117510352-A | Synthesis method of D-2, 3-diaminopropionic acid | 浙江永太科技股份有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220331290-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SARCOPENIA, CONTAINING UNNATURAL AMINO ACID | MYO-TEC-SCI (KR) | 2022-10-20 | — | — | US | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| US-20210253577-A1 | BIODEFENSE AGENTS | BioVersys AG (CH) | 2021-08-19 | — | — | US | disclosed |
| US-10815237-B2 | Antimicrobials and methods of making and using same | BioVersys AG (CH) | 2020-10-27 | — | — | US | disclosed |
| CN-109206617-B | Method for resolving racemic compound by fractional crystallization | 北京大学 | 2020-04-24 | — | — | CN | disclosed |
| US-20190194205-A1 | ANTIMICROBIALS AND METHODS OF MAKING AND USING SAME | MELINTA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| EP-3452478-A1 | ANTIMICROBIALS AND METHODS OF MAKING AND USING SAME | Melinta Therapeutics, Inc. (US) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017193017-A1 | ANTIMICROBIALS AND METHODS OF MAKING AND USING SAME | MELINTA THERAPEUTICS, INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| EP-0973936-A1 | COMBINATORIAL LIBRARIES OF PEPTIDOMIMETIC AMINOTHIOETHER ACIDS | ELI LILLY AND COMPANY (US) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998046786-A1 | COMBINATORIAL LIBRARIES OF PEPTIDOMIMETIC AMINOTHIOETHER ACIDS | ELI LILLY AND COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
| US-5250517-A | Hypotensive and cardiotonic agents; cardiac insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1993-10-05 | — | — | US | disclosed |
| US-4864031-A | Process for the resolution of D,L-racemic mixtures | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 1989-09-05 | — | — | US | disclosed |
| EP-0225503-B1 | RESOLUTION SYSTEM | YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED (IL) | 1989-08-02 | — | — | EP | disclosed |
| US-4533506-A | Resolution of amino acids | YEDA RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 1985-08-06 | — | — | US | disclosed |
| US-4390722-A | CRYSTALLIZATION FROM SUPERSATURATED SOLUTION USING AMINO ACID AS AS CRYSTAL INHIBITOR | YEDA RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 1983-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194205-A1 | ANTIMICROBIALS AND METHODS OF MAKING AND USING SAME | LPO, OAT, MPO | GRIK1 3615/4885GRIK2 4232/4885PTGS1 907/4885 |
| US-10815237-B2 | Antimicrobials and methods of making and using same | LPO, OAT, MPO | GRIK1 3615/4885GRIK2 4232/4885PTGS1 907/4885 |
| US-12152031-B2 | Biodefense agents | BPGM, DDT, UNG | GRIK1 4488/4885GRIK2 4555/4885PTGS1 1571/4885 |
| US-12104022-B2 | Chiral resolution method mimicking magnetic beneficiation and the magnetic nano-inhibitors for selective enrichment | NES, ALB, NAF1 | GRIK1 3481/4885GRIK2 3435/4885PTGS1 4851/4885 |
| US-20210253577-A1 | BIODEFENSE AGENTS | BPGM, DDT, UNG | GRIK1 4488/4885GRIK2 4555/4885PTGS1 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.